The U.S. mRNA therapeutics CDMO market is projected to grow significantly, reaching a valuation of $6.27 billion by 2033, driven by a CAGR of 15.01% from 2025 to 2033. The market is witnessing a shift towards diverse applications beyond pandemic responses, with a focus on new vaccines and oncology treatments. Specialized CDMOs are crucial partners for asset-light biotechs, facilitating the advancement of next-generation mRNA therapies from clinical development to commercialization.
The market’s bright outlook is supported by a robust clinical pipeline, with over 1,500 mRNA programs in development as of early 2024. Moderna, a key player in the industry, has multiple programs in late-stage development, with plans for potential product approvals in 2025 and beyond. The company aims to secure up to 10 product approvals by 2027, ensuring sustained engagement with CDMOs for manufacturing needs.
Financial commitments and infrastructure expansions by industry players like Lonza, coupled with significant venture capital investments in biotechs like Strand Therapeutics and Centivax, underscore the market’s growth potential. Government funding, such as BARDA’s awards to companies like Moderna for vaccine development, further bolsters manufacturing capabilities to meet the increasing demand for mRNA therapeutics.
Key Takeaways:
– The U.S. mRNA therapeutics CDMO market is poised to reach $6.27 billion by 2033, growing at a CAGR of 15.01%.
– A robust clinical pipeline with over 1,500 mRNA programs is driving the demand for CDMO services.
– Financial investments from industry players and government funding are accelerating manufacturing capacities for mRNA therapies.
– Strategic partnerships and infrastructure expansions by CDMOs are essential to meet the growing demand for next-generation mRNA therapeutics.
Tags: clinical trials, lipid nanoparticles, cost of goods, regulatory, validation, quality control, biotech
Read more on finance.yahoo.com